A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963
This study is recruiting at 14 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ovarian Cancer
- Breast Cancer
- Endometrial Cancer
- Non-Small Cell Lung Cancer
- Advanced or Metastatic Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- LigaChem Biosciences, Inc.
- Last updated on ClinicalTrials.gov
- October 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Kentucky · 1
- St. Elizabeth Healthcare · Edgewood, KY
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Missouri · 1
- Washington University, Siteman Cancer Center · St Louis, MO
New York · 3
- Roswell Park Comprehensive Cancer Center · Buffalo, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
- Mount Sinai Tisch Cancer Center · New York, NY
Ohio · 1
- Cleveland Clinic Taussig Cancer Institute · Cleveland, OH
Pennsylvania · 2
- Sidney Kimmel Comprehensive Center at Jefferson · Philadelphia, PA
- UPMC · Pittsburgh, PA
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Texas · 2
- MD Anderson · Houston, TX
- UT Health San Antonio - MD Anderson Cancer Center · San Antonio, TX
Utah · 1
- Intermountain/LDS Hospital Ph 1 Research Program · Salt Lake City, UT
Virginia · 1
- Inova Schar Cancer Institute · Falls Church, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.